Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway.

Content Provider	Europe PMC
Author	Huang, Anwu Wang, Zhaolin Tang, Hua Jia, Zhuyin Ji, Xiaojun Yang, Xuehua Jiang, Wenbing
Copyright Year	2023
Abstract	Background Myocardial ischemia/reperfusion (I/R) injury is a severe heart problem resulting from restoring coronary blood flow to the myocardium after ischemia. This study is aimed at ascertaining the therapeutic efficiency and action mechanism of bardoxolone methyl (BARD) in myocardial I/R injury. Methods In male rats, myocardial ischemia was performed for 0.5 h, and then, reperfusion lasted for 24 h. BARD was administrated in the treatment group. The animal's cardiac function was measured. Myocardial I/R injury serum markers were detected via ELISA. The 2,3,5-triphenyltetrazolium chloride (TTC) staining was used to estimate the infarction. H&E staining was used to evaluate the cardiomyocyte damage, and Masson trichrome staining was used to observe the proliferation of collagen fiber. The apoptotic level was assessed via the caspase-3 immunochemistry and TUNEL staining. Oxidative stress was measured through malondialdehyde, 8-hydroxy-2′-deoxyguanosine, superoxide dismutase, and inducible nitric oxide synthases. The alteration of the Nrf2/HO-1 pathway was confirmed via western blot, immunochemistry, and PCR analysis. Results The protective effect of BARD on myocardial I/R injury was observed. In detail, BARD decreased cardiac injuries, reduced cardiomyocyte apoptosis, and inhibited oxidative stress. For mechanisms, BARD treatment significantly activates the Nrf2/HO-1 pathway. Conclusion BARD ameliorates myocardial I/R injury by inhibiting oxidative stress and cardiomyocyte apoptosis via activating the Nrf2/HO-1 pathway.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9977528&blobtype=pdf
ISSN	17555914
Journal	Cardiovascular Therapeutics [Cardiovasc Ther]
Volume Number	2023
DOI	10.1155/2023/5693732
PubMed Central reference number	PMC9977528
PubMed reference number	36874247
e-ISSN	17555922
Language	English
Publisher	Hindawi
Publisher Date	2023-02-22
Access Restriction	Open
Rights License	This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2023 Anwu Huang et al.
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical) Cardiology and Cardiovascular Medicine